GlassScriptPhysician profile
Torrie Furman
NPI 1932489325
$1,619.51
in general payments reported to CMS, 2019-2025
27 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $497 · 2022: $95.40 · 2023: $226 · 2024: $313 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.57 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $186.57 | 2021 | |
| Pfizer INC. | $178.55 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $176.15 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $145.45 | 2023-2025 | Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $113.29 | 2021-2025 | |
| Endo USA, INC. | $94.36 | 2025 | Xiaflex |
| Urogen Pharma, INC. | $90.75 | 2024-2025 | |
| Astellas Pharma US INC | $84.07 | 2024-2025 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $75.61 | 2021 | |
| Urovant Sciences INC | $53.24 | 2022 | |
| Procept Biorobotics Corporation | $50.94 | 2023-2025 | Aquabeam Robotic System |
| Abbvie INC. | $46.24 | 2021-2022 | |
| Coloplast Corp | $44.87 | 2022-2025 | |
| Axonics, INC. | $42.92 | 2024 | Axonics |
| Ambu INC. | $33.90 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.51 | 2021 | |
| Convatec INC. | $23.65 | 2023 | |
| Progenics Pharmaceuticals, INC. | $22.98 | 2025 | |
| Calyxo, INC. | $20.94 | 2025 | Cvac Aspiration System |
| Myriad Genetic Laboratories, INC. | $17.12 | 2023 | Prolaris |
| Davol INC. | $16.96 | 2025 | Arista |
| Pear Therapeutics (US), INC. | $15.70 | 2021 | |
| Antares Pharma, INC. | $14.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.62 | 2021 | |
| Genentech USA, INC. | $12.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.06 | 2021 | |
| Boston Scientific Corporation | $10.40 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Torrie Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.